- Home
- LONA vs IGI Comparison
LONA vs IGI Comparison
Compare LONA & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LONA | IGI |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | 26 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.7M | 96.4M |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | LONA | IGI |
|---|---|---|
| Price | $10.04 | $16.14 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 28.0K | 26.7K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.21 | $15.78 |
| 52 Week High | $14.21 | $17.09 |
Technical Indicators
Market Signals| Indicator | LONA | IGI |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 49.74 |
| Support Level | $7.88 | $15.78 |
| Resistance Level | $12.47 | $16.59 |
| Average True Range (ATR) | 0.80 | 0.17 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 85.93 | 44.33 |
Price Performance
Historical ComparisonAbout LONA LeonaBio Inc. Common Stock
LeonaBio Inc is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.